Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total
body irradiation, before peripheral blood stem cell transplant helps stop the growth of
cancer cells. It may also stop the patient's immune system from rejecting the donor's stem
cells. When the healthy stem cells and natural killer (NK) cells from a donor are infused
into the patient they may help the patient's bone marrow make stem cells, red blood cells,
white blood cells, and platelets. Giving IL-2 (aldesleukin) after NK cell infusion may
stimulate them to kill any remaining cancer cells.
PURPOSE: This phase I/II (currently enrolling in phase II) trial is studying how well a donor
natural killer cell infusion works in treating patients who are undergoing donor stem cell
transplant for acute myeloid leukemia.